Book a Meeting
Creative Biolabs - ADCC+ Antibody

Anti-EGFL7 Antibody, Non-Fucosylated (BioBet-196ZP) (CAT#: BioBet-196ZP) Datasheet

Target
EGFL7
Isotype
IgG1, κ
Description
Anti-EGFL7 Antibody, Non-Fucosylated (BioBet-196ZP) is a humanized monoclonal IgG1, κ antibody against EGFL7. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Solid tumors
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EGFL7 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
EGFL7
Full Name
EGF Like Domain Multiple 7
Background
This gene encodes a secreted endothelial cell protein that contains two epidermal growth factor-like domains. The encoded protein may play a role in regulating vasculogenesis. This protein may be involved in the growth and proliferation of tumor cells. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012]
Alternative Names
Parsatuzumab; 1312797-14-0; RG7414; MEGF0444A; EGFL7; EGF-like-domain, multiple 7; epidermal growth factor-like protein 7; ZNEU1; EGF-like protein 7; NOTCH4-like protein; vascular endothelial statin; multiple EGF-like domains protein 7;
Gene ID
51162
UniProt ID
Q9UHF1
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with EGFL7 include Carotid Artery Disease.
Related Pathways
Gene Ontology (GO) annotations related to this gene include calcium ion binding and Notch binding. An important paralog of this gene is EGFL8.
Function
Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis.
Post-translational modifications
1. Glycosylation at Thr54, Thr55, and Thr190 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-196ZP
Host
Humanized
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human EGFL7. Parsatuzumab is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.
Antibody Indication
Solid tumors

Solid tumors

Related Products

Anti-EGFL7 Antibody, Highly Galactosylated (BioBet-GA-196ZP) (CAT#: BioBet-GA-196ZP)
Anti-EGFL7 Antibody, On-Target (AES-0622-ZP852) (CAT#: AES-0622-ZP852)
Anti-EGFL7 Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP524) (CAT#: AES-0622-ZP524)
Anti-EGFL7 Antibody, Recycling (AES-0622-ZP196) (CAT#: AES-0622-ZP196)
Anti-EGFL7 Antibody, Half-Life Extended (AES-0622-ZP1180) (CAT#: AES-0622-ZP1180)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *

ISO 9001 Certified - Creative Biolabs Quality Management System.
© 2025 Creative Biolabs. All rights reserved.
Merry Christmas Merry Christmas